PROK
PROKIDNEY CORP.
NASDAQ · Healthcare · Biotechnology · US
$1.10
+2.34%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$1.09
From 52W high−62.11%
Volume780851.00
Market cap$228.78M
P/E (TTM)—
P/S (TTM)279.7x
Div yield—
Key dataNov 4, 2026
Open
$1.09
From 52W high
−62.11%
Volume
780851.00
Market cap
$228.78M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−7.2x
P/E (TTM)
—
RSI (14)
27.6
MomentumView details →
1D Return
+2.34%
YTD Return
−54.02%
SummaryUpdated Jun 1, 2026
ProKidney Corp. (NASDAQ:PROK) is a clinical-stage biotechnology company founded in 2015 and headquartered in Winston-Salem, North Carolina. The company went public in June 2021 and focuses on developing innovative cellular therapy treatments for kidney diseases. ProKidney is currently advancing its lead product candidate, Renal Autologous Cell Therapy (REACT), through Phase III clinical trials for diabetic kidney disease, representing a potentially groundbreaking approach to treating chronic kidney conditions that affect millions of patients worldwide.
Similar companies
Latest newsMore news →
PROKIDNEY CORP. entered into an at-the-market sale agreement with JEFFERIES LLC to offer up to $200 million of its Class A common stock, with Jefferies receiving compensation of up to 3.0% of gross proceeds.6d agoProKidney announced that it will host a virtual key opinion leader event on October 27, 2026, at 10:30 a.m. ET.13d ago